Juno Pharmaceuticals today announced it has acquired the Amneal injectables, ophthalmic, and oncology portfolio. This business primarily has a focus on Australian hospital customers.

“Juno is excited to add the Amneal Australia’s hospital injectable, ophthalmic, and oncology range to its growing portfolio. The Amneal range complements many of the current Juno assets and Juno is particularly excited to be managing products such as Bicnu (carmustine)” says CEO and Managing Director, Mark Crotty.

Juno is a rapidly growing local Australian business which recorded its first full year of commercial sales in 2016. Juno’s business model is based on partnering, including with international and local generic suppliers and innovative discovery companies, and has a focus on local Australian hospital customer needs. The acquisition of select Amneal products is Juno’s first since its formation in 2013. When added to the existing portfolio and strong pipeline, the acquisition positions Juno as one of the largest generic injectable product hospital suppliers in the Australian market.

The acquisition takes effect from August 31st, 2017. Juno will work with Amneal to ensure a smooth transition of the business with suppliers and customers.

For all queries please contact:

Mark Crotty, +61424 152 881